Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Descending) Package Effective Date Package Discontinuation Date Status
68001-0610-25 68001-0610 Zoledronic acid Zoledronic acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Feb. 28, 2024 In Use
70860-0214-61 70860-0214 Melphalan hydrochloride Melphalan hydrochloride 50.0 mg/10ml Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 30, 2019 Oct. 31, 2025 In Use
00009-0082-02 00009-0082 Irinotecan hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 24, 2024 In Use
00143-9167-01 00143-9167 Eribulin mesylate ERIBULIN MESYLATE 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous June 28, 2024 In Use
00480-3290-01 00480-3290 Paclitaxel Paclitaxel 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous July 2, 2024 In Use
00781-3520-91 00781-3520 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2024 May 25, 2024 In Use
00781-3528-10 00781-3528 Cyclophosphamide Cyclophosphamide 500.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 8, 2024 In Use
00781-3529-10 00781-3529 Cyclophosphamide Cyclophosphamide 1000.0 mg/10mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 8, 2024 In Use
00781-3530-10 00781-3530 Cyclophosphamide Cyclophosphamide 2000.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 8, 2024 In Use
60505-6287-02 60505-6287 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous April 23, 2024 In Use
60505-6287-04 60505-6287 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous April 23, 2024 In Use
31722-0362-31 31722-0362 MELPHALAN HYDROCHLORIDE MELPHALAN HYDROCHLORIDE 50.0 mg/10ml Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 23, 2024 In Use
43598-0671-11 43598-0671 Fosaprepitant Fosaprepitant 150.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 20, 2020 In Use
50881-0013-01 50881-0013 Tafasitamab-cxix MONJUVI 200.0 mg/5mL Immunotherapy Monoclonal Antibody CD19 Intravenous Aug. 5, 2020 In Use
70121-2631-01 70121-2631 FOSAPREPITANT DIMEGLUMINE FOCINVEZ 150.0 mg/50mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous June 15, 2024 In Use
71288-0165-53 71288-0165 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 10, 2023 Jan. 2, 2025 In Use
71288-0165-54 71288-0165 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 10, 2023 In Use
72266-0152-01 72266-0152 Zoledronic acid Zoledronic acid 5.0 mg/100mL Ancillary Therapy Bisphosphonate Intravenous June 12, 2023 In Use
82449-0231-01 82449-0231 FOSAPREPITANT DIMEGLUMINE FOCINVEZ 150.0 mg/50mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous June 26, 2024 In Use
83634-0777-05 83634-0777 Palonosetron hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 15, 2024 In Use
83634-0779-02 83634-0779 Metoclopramide hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous June 30, 2024 In Use
83703-0531-02 83703-0531 Palonosetron hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov. 12, 2021 In Use
83831-0111-01 83831-0111 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 28, 2024 In Use
83831-0112-01 83831-0112 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 28, 2024 In Use
55513-0059-01 55513-0059 Tarlatamab-dlle IMDELLTRA (AMG757) 1.0 mg/1 Immunotherapy T Cell Receptor (TCR) DLL3, CD3 Intravenous May 16, 2024 In Use

Found 10,000 results in 9 milliseconds — Export these results